TD Asset Management Inc Has $4.08 Million Holdings in Immunome, Inc. (NASDAQ:IMNM)

Key Points

• TD Asset Management Inc has increased its ownership of Immunome, Inc. by 43.3%, acquiring an additional 183,460 shares, bringing its total holdings to approximately 606,762 shares worth $4,084,000.
• Insider activity reported that Director Jean Jacques Bienaime bought 5,000 shares of Immunome at an average price of $9.38 per share, marking a 15.92% increase in his position.
• Immunome has a current market capitalization of $921.44 million and shows volatile performance, with a one-year price range between $5.15 and $16.73.

TD Asset Management Inc boosted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 43.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 606,762 shares of the company's stock after buying an additional 183,460 shares during the period. TD Asset Management Inc owned about 0.70% of Immunome worth $4,084,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Enavate Sciences GP LLC acquired a new stake in shares of Immunome during the 4th quarter worth about $36,939,000. JPMorgan Chase & Co. increased its holdings in Immunome by 2,540.4% during the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock valued at $6,888,000 after purchasing an additional 624,045 shares in the last quarter. Granahan Investment Management LLC bought a new stake in shares of Immunome during the fourth quarter worth $3,337,000. Renaissance Technologies LLC raised its holdings in shares of Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock valued at $3,356,000 after buying an additional 304,700 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Immunome by 127.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company's stock worth $5,310,000 after acquiring an additional 280,000 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Stock Performance

NASDAQ IMNM traded down $0.52 during trading hours on Wednesday, reaching $10.33. 266,013 shares of the company's stock were exchanged, compared to its average volume of 1,026,439. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.73. The company's 50-day moving average is $9.48 and its two-hundred day moving average is $8.91. The company has a market capitalization of $898.81 million, a price-to-earnings ratio of -3.25 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The firm had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. Research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime purchased 5,000 shares of Immunome stock in a transaction on Tuesday, June 3rd. The stock was purchased at an average price of $9.38 per share, with a total value of $46,900.00. Following the transaction, the director directly owned 36,415 shares in the company, valued at $341,572.70. The trade was a 15.92% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 8.60% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on IMNM shares. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Wedbush restated an "outperform" rating and set a $21.00 target price (down previously from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.